

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Glofitamab monotherapy = 5 or fewer
- Glofitamab + Gemcitabine + Oxaliplatin = 0

Question:

2. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Acalabrutinib (Calquence) = 5 or fewer
- Ibrutinib (Imbruvica) = 5 or fewer
- Pirtobrutinib (Jaypirca) = 0
- Venetoclax (Venclyxto) = 5 or fewer
- Zanubrutinib (Brukinsa) = 9
- Rituximab = 59
- Obinutuzumab (Gazyvaro) = 0

Question:

3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
*Lothian NHS Board is the common
name of Lothian Health Board*

Answer:

- Acalabrutinib (Calquence) = 5 or fewer
- Ibrutinib (Imbruvica) = 5 or fewer
- Pirtobrutinib (Jaypirca) = 0
- Venetoclax (Venclyxto) = 5 or fewer
- Zanubrutinib (Brukinsa) = 5 or fewer
- Obinutuzumab (Gazyvaro) = 0
- Rituximab = 5 or fewer

Question:

4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Ibrutinib + Venetoclax = 0
- Obinutuzumab + Venetoclax = 8
- Ibrutinib monotherapy / maintenance = 5 or fewer
- Venetoclax monotherapy = 5 or fewer
- Venetoclax + Rituximab = 5 or fewer
- Rituximab monotherapy = 5 or fewer
- Rituximab + Fludarabine + Cyclophosphamide = 0
- Rituximab + R-CHOP = 0
- Rituximab + Bendamustine = 0
- Rituximab + Chlorambucil = 0
- Obinutuzumab + Chlorambucil = 0
- Acalabrutinib + Venetoclax = 0
- Acalabrutinib + Venetoclax + Obinutuzumab = 0

Question:

5. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Answer:

- Acalabrutinib = 5 or fewer
- Ibrutinib = 0
- Zanubrutinib = 5 or fewer
- Ibrutinib + R-CHOP / R-DHAP = 0
- Pirtobrutinib = 0



To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive